Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159573 · ClinicalTrials.gov registry record
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 530
- Enrollment target
NCT02159573 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 530 participants.
The verdict
NCT02159573 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 530 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The secondary objective is to further evaluate relapse activity, defined as annualized relapse rate (ARR), hospitalization and intravenous corticosteroid use, during the first year of Tecfidera treatment following transition from Tysabri treatment.
Interventions
- DRUG dimethyl fumarate
- BIOLOGICAL natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159573
The ClinicalTrials.gov registry entry for NCT02159573 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dimethyl fumarate is the first listed.
NCT02159573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159573 about?
NCT02159573 is a clinical study titled "Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)". The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (BG00002) to Tecfidera (BG00012) in the real-world setting. The seco...
What is the current status of trial NCT02159573?
This trial is currently completed. The enrollment target is 530 participants. The study started on 2014-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02159573?
The interventions under investigation include: dimethyl fumarate (DRUG), natalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02159573?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.